MedTrace Logo

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer

NCT03951415 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-04-01

No results posted yet for this study

Summary

The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of the combination therapy of olaparib tablets and durvalumab IV.

Conditions

  • Endometrial Neoplasms
  • Uterine Neoplasms
  • Endometrium Cancer

Interventions

DRUG

PARP inhibitor and Anti-PD-L1

olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks

Sponsors & Collaborators

  • Amsterdam University Medical Center

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Leiden University Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951415 on ClinicalTrials.gov